Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $6.35, up 6.90% from its previous closing price of $5.94. In other words, the price has increased by $6.90 from its previous closing price. On the day, 14.89 million shares were traded. RXRX stock price reached its highest trading level at $6.44 during the session, while it also had its lowest trading level at $6.04.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.81 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’25 when Gibson Christopher sold 20,000 shares for $6.58 per share. The transaction valued at 131,600 led to the insider holds 1,256,024 shares of the business.
Gibson Christopher sold 20,000 shares of RXRX for $127,400 on Mar 06 ’25. The Chief Executive Officer now owns 1,256,024 shares after completing the transaction at $6.37 per share. On Mar 06 ’25, another insider, Gibson Christopher, who serves as the Officer of the company, bought 20,000 shares for $6.37 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2552642816 and an Enterprise Value of 2066782720. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.38 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 35.126 whereas that against EBITDA is -4.671.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.95, which has changed by -0.44395798 over the last 52 weeks, in comparison to a change of 0.09506309 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -15.25%, while the 200-Day Moving Average is calculated to be -13.02%.
Shares Statistics:
It appears that RXRX traded 23.57M shares on average per day over the past three months and 20649460 shares per day over the past ten days. A total of 389.55M shares are outstanding, with a floating share count of 305.79M. Insiders hold about 23.93% of the company’s shares, while institutions hold 60.17% stake in the company. Shares short for RXRX as of 1740700800 were 80716710 with a Short Ratio of 3.42, compared to 1738281600 on 63748978. Therefore, it implies a Short% of Shares Outstanding of 80716710 and a Short% of Float of 21.83.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
